Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 22:42, 13 November 2011 (Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.

References

1. Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI; Sattler, F (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
2. ClinicalTrials.gov

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Antiinfective agent stubs
• Monoclonal antibody stubs